• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Neurocrine Biosciences

Neurocrine Biosciences

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: Neurocrine Biosciences' new drug may cost patients more than $10,000 a month, twice as much as expected

    UPDATE: Neurocrine Biosciences' new drug may cost patients more than $10,000 a month, twice as much as expected

  2. UPDATE: Neurocrine Biosciences' new drug may cost patients more than $10,000 a month, twice as much as expected

    UPDATE: Neurocrine Biosciences' new drug may cost patients more than $10,000 a month, twice as much as expected

  3. UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

    UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

  4. UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

    UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

  5. UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

    UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

  6. UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

    UPDATE: Pharma companies are seeking a new treatment -- for the backlash against high drug prices

  7. No one is noticing this big red flag for the stock market

    No one is noticing this big red flag for the stock market

  8. CLS: Slow Down, Think Before You Trade

    On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...

©2017 Morningstar Advisor. All right reserved.